GSK Presents New Data from the GARNET Study Demonstrating Potential of Dostarlimab to Treat a Subset of Women with Recurrent or Advanced Endometrial Cancer

London, UK 23 April 2020 -- GlaxoSmithKline plc today announced data from an updated analysis of the GARNET trial, which demonstrated that dostarlimab, an investigational anti-programmed death-1 (PD-1

Latest News Clinical News 1131
Read All

Moderna Announces IND Submitted to U.S. FDA for Phase 2 Study of mRNA Vaccine (mRNA-1273) Against Novel Coronavirus

CAMBRIDGE, Mass.--(BUSINESS WIRE) - Apr. 27, 2020 -- Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new gene

Latest News Clinical News 802
Read All

Genentech’s Risdiplam Shows Significant Improvement in Survival and Motor Milestones in Infants With Type 1 Spinal Muscular Atrophy (SMA)

South San Francisco, CA -- April 27, 2020 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today presented 1-year data from FIREFISH Part 2, a pivotal global study evaluating ri

Latest News Clinical News 817
Read All

Tonix Pharmaceuticals Achieves 50 Percent Enrollment in Phase 3 RELIEF Study of TNX-102 SL (Cyclobenzaprine HCl Sublingual Tablets) for Management of Fibromyalgia

NEW YORK, April 24, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that 50 percent of t

Latest News Clinical News 721
Read All

Theravance Biopharma Announces First Subject Dosed in Phase 1 Study of TD-0903, in Development for the Treatment of Hospitalized Patients with Acute Lung Injury Caused by COVID-19

DUBLIN and SOUTH SAN FRANCISCO, Calif., April 23, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company"), a diversified biopharmac

Latest News Clinical News 767
Read All

AstraZeneca and Saint Luke’s Mid America Heart Institute Initiate Phase III DARE-19 Trial with Farxiga in COVID-19 Patients

23 April 2020 -- AstraZeneca and Saint Luke’s Mid America Heart Institute have initiated a randomised, global Phase III trial to assess the potential of Farxiga (dapagliflozin) as a treatment in patie

Latest News Clinical News 965
Read All

BioNTech and Pfizer Announce Regulatory Approval from German Authority Paul-Ehrlich-Institut to Commence First Clinical Trial of COVID-19 Vaccine Candidates

MAINZ, Germany and NEW YORK, April 22, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) and Pfizer Inc. (NYSE: PFE), have announced today that the German regulatory aut

Latest News Clinical News 887
Read All

ERYTECH Provides Update on the TRYbeCA-1 Phase 3 Clinical Trial of Eryaspase in Second Line Pancreatic Cancer

LYON, France, April 20, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma(Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing red blood cell-based cancer therapeutics, today prov

Latest News Clinical News 778
Read All

Sinovac Announces Commencement of Phase I Human Clinical Trial for Vaccine Candidate Against COVID-19

BEIJING -- April 17, 2020 -- Sinovac Biotech Ltd. (NASDAQ:SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that the Company has commenced P

Latest News Clinical News 879
Read All

FDA Accepts for Priority Review Biologics License Application for REGN-EB3 to Treat Ebola

TARRYTOWN, N.Y., April 16, 2020 /PRNewswire/ -- REGN-EB3 developed via same rapid response platform currently being leveraged to develop novel COVID-19 antibody therapy Regeneron Pharmaceuticals, Inc.

Latest News Clinical News 836
Read All

Mayne Pharma Submits NDA for E4/DRSP to the FDA

16 April 2020, Adelaide Australia and Liege, Belgium -- Mayne Pharma Group Limited (ASX: MYX) and Mithra Pharmaceuticals, SA (Euronext Brussels: MITRA) today announced that Mayne Pharma has submitted

Latest News Clinical News 1280
Read All

First Patient Treated with Leronlimab in Phase 2b/3 Trial for COVID-19

VANCOUVER, Washington, April 15, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 ant

Latest News Clinical News 846
Read All
News
- CLINIEXPERT -
Int'l Clinical Service Expert

We are the leader
Because of our professionism